Navigation Links
Genomic Health to Announce Fourth Quarter and Year-End 2012 Financial Results and Host Conference Call on Wednesday, February 6, 2013
Date:1/30/2013

REDWOOD CITY, Calif., Jan. 30, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Wednesday, February 6 at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end 2012 financial results.  The call and webcast will follow the release of the fourth quarter financial results after market close.

Conference Call Details
To access the live conference call on February 6 at 4:30 p.m. Eastern Time via phone, please dial (877) 303-7208 from the United States and Canada or +1(224) 357-2389 internationally.  Please dial in approximately ten minutes prior to the start of the call. 

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company's website at http://investor.genomichealth.com.  Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

About Genomic Health 

Genomic Health, Inc. (NASDAQ: GHDX) is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions.  The company's lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carci
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Empire Genomics Chooses Funakoshi as Japan Distributor
2. Genomic Health to Announce First Quarter 2012 Financial Results and Host Conference Call on Wednesday, May 2, 2012
3. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
4. Rubicon Genomics Launches ThruPLEX™ Family of Sample Preparation Products for Next Generation Sequencing Applications
5. Gentris Corporation Launches New Pharmacogenomics Services
6. Life Technologies Signs Collaborative Agreement with Structural Genomics Consortium to Develop First Antibody Master Set for Epigenetic Studies
7. Life Technologies Acquires Pinpoint Genomics and CLIA-Approved Lung Cancer Test
8. Elsevier Launches New Open Access Journal: Applied and Translational Genomics
9. Genomic Health to Announce Second Quarter 2012 Financial Results and Host Conference Call on Wednesday, August 8, 2012
10. Genomic Health to Present at the Canaccord Genuity Growth Conference
11. Frost & Sullivan Recognizes Rosetta Genomics for Its Strategic Excellence and Strong Contribution to Next-Generation Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014  Halozyme Therapeutics, Inc. (NASDAQ: ... and dosing of patients in its ongoing Phase 2 ... cancer under the revised clinical protocol agreed to with ... form of Halozyme,s proprietary recombinant human hyaluronidase under development ... "Our diligent effort to rapidly re-initiate ...
(Date:7/22/2014)... , July 22, 2014  Neurotrope Bioscience, Inc., a ... world-wide, exclusive license agreement with the Icahn School of ... Mount Sinai ) to utilize its proprietary ... in the treatment of Niemann-Pick Type C Disease (NPC), ... with Alzheimer-like symptoms. The license also covers other diseases ...
(Date:7/22/2014)... BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: ... has appointed Charles J. (Chuck) Bramlage and ... the Board.  Mr. Bramlage is a ... sales and other commercial functions.  He is currently the ... stage company that was recently acquired by AstraZeneca and ...
Breaking Medicine Technology:Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 2BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 3BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 4BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 5BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 6BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 7
... WOONSOCKET, R.I., Oct. 18, 2011 A recent ... up germs, they are not doing all they can to ... receiving an annual flu shot as recommended by the Centers ... http://photos.prnewswire.com/prnh/20100816/NE50800LOGO) The CDC recommends that anyone ages 6 ...
... With connectivity enabled by Unlimited Systems Interlink integration ... only helps cancer clinics easily meet many of the ... saves time and money by reducing duplicate data entry, ... claims payment and reduced denials. Clinics can ...
Cached Medicine Technology:CVS/pharmacy Survey Reveals Consumer Misconceptions Standing in the Way of Getting a Flu Shot 2CVS/pharmacy Survey Reveals Consumer Misconceptions Standing in the Way of Getting a Flu Shot 3CVS/pharmacy Survey Reveals Consumer Misconceptions Standing in the Way of Getting a Flu Shot 4Navigating Cancer and Unlimited Systems Partner to Provide Cancer Clinics With IT Interoperability to Attain HITECH Act Incentives 2
(Date:7/22/2014)... Steven Reinberg HealthDay Reporter ... that break up blood clots deep in the veins of ... However, one results in a greater risk of bleeding and ... the other treatment, a new study finds. The standard ... (DVT) -- is blood-thinning medications and compression stockings. The other, ...
(Date:7/22/2014)... undergoing a minimally invasive hysterectomy using electric power morcellation, ... at the time of the procedure, according to a ... concern that this procedure, in which the uterus is ... of undetected malignancies. , Despite the commercial availability of ... the prevalence of malignancy at the time of electric ...
(Date:7/22/2014)... The American Society of Hematology (ASH) will present the ... for Lifetime Achievement in Hematology, to Kanti R. Rai, ... School of Medicine for his 50-year career combining landmark ... and exceptional patient care. , The Wallace H. ... on an individual who has been a vital contributor ...
(Date:7/22/2014)... mechanisms with cancer, according to a new report by ... , published in PLOS ONE on July ... very same inhibitors of apoptosis, or cell destruction, in ... diseases. Henry Kaminski, M.D. , chair of the ... and Health Sciences (SMHS), as well as colleagues from ...
(Date:7/22/2014)... Ticket Down is a reliable source ... Fedex Field in Landover, MD. There has never been a ... international soccer. After the success of the American national soccer team ... and well. One way that fans of the world’s sport will ... the 2014 Guinness International Champions Cup. The tournament will kick off ...
Breaking Medicine News(10 mins):Health News:Study Casts Doubt on Costly Treatment for Leg Clots 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 3Health News:Study examines presence of uterine cancers at the time of hysterectomy using morcellation 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:New research finds pathogenic connection between autoimmune disorders and cancer 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 3
... of patients whose myelodysplastic syndrome is related to earlier ... have a poor prognosis, researchers from The University of ... Annual Meeting of the American Society of Hematology. ... or both treatments are usually told that they have ...
... of biological macromolecules are the central bases of ... cells by linking many small molecules together. Naturally ... A detailed understanding of the synthesis of these ... for understanding biological systems, and for the development ...
... smells apart is no problem for the human nose. How ... by an interdisciplinary team of researchers at the RUB. The ... of the three-dimensional structure of the binding site of an ... pattern of hydrogen bonds between odorant and receptor, which accounts ...
... News) -- Undiagnosed chronic fatigue syndrome may account for up ... for extended periods of time and are not truant or ... out of school, a new study reveals. For the ... 16 at three secondary schools in England and concluded that ...
... US Prostate Cancer Prevention Trial found cancer in many men ... which PSA level should lead to a biopsy recommendation. ... considerable controversy, that the evidence does not support recommending PSA ... the risks outweigh the benefits. Now, a study shows ...
... - Adding a drug that activates genes to frontline combination ... remission rate after initial treatment, researchers at The University of ... Meeting of the American Society of Hematology. Results of ... stage for a national Phase III clinical trial of the ...
Cached Medicine News:Health News:Prognostic model developed for MDS related to prior cancer therapy 2Health News:Prognostic model developed for MDS related to prior cancer therapy 3Health News:Visualization of DNA synthesis in vivo 2Health News:A good nose: RUB-Researchers decipher interaction of fragrances and olfactory receptors 2Health News:Chronic Fatigue Tied to Extended School Absences 2Health News:Biopsy referral after PSA screening stays consistent over time 2Health News:AML patients have high response rate with vorinostat added to treatment 2
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
A straightforward, versatile approach to arthroscopically assisted pin placement in either the ankle or wrist....
... SureStep Drug Screen Tests are available in ... MDMA (Ecstasy). Designed using Microgenics Antibody Technology, ... only point of care immunoassay targeted to ... both MDA and MDEA but no cross-reactivity ...
Medicine Products: